Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL

Given the poor outcome of refractory and relapsing T-cell acute lymphoblastic leukemia (TALL), identifying prognostic markers is still challenging. Using single nucleotide polymorphism (SNP) array analysis, we provide a comprehensive analysis of genomic imbalances in a cohort of 317 newly diagnosed patients with T-ALL including 135 children and 182 adults with respect to clinical and biological features and outcomes. SNP array results identified fi ed at least 1 somatic genomic imbalance in virtually all patients with T-ALL (-96%). Del(9)(p21) (-70%) and UPD(9)p21)/CDKN2A/B (-28%) were the most frequent genomic imbalances. Unexpectedly del(13)(q14)/RB1/DLEU1 (-14%) was the second most frequent copy number variant followed by del(6)(q15)/CASP8AP2 (-11%), del(1)(p33)/SIL-TAL1 (-11%), del(12)(p13)ETV6/CDKN1B (-9%), del(18)(p11)/PTPN2 (-9%), del(1)(p36)/RPL22 (-9%), and del(17)(q11)/NF1/SUZ12 (-8%). SNP array also revealed distinct profiles fi les of genomic imbalances according to age, immunophenotype, and oncogenetic subgroups. In particular, adult patients with T-ALL demonstrated a significantly fi cantly higher incidence of del(1)(p36)/RPL22, and del(13)(q14)/RB1/DLEU1, and lower incidence of del(9)(p21) and UPD(9p21)/CDKN2A/B. We determined a threshold of 15 genomic imbalances to stratify patients into high- and low- risk groups of relapse. Survival analysis also revealed the poor outcome, despite the low number of affected cases, conferred by the presence of chromothripsis (n = 6,-2%), del(16)(p13)/CREBBP (n = 15,-5%) as well as the newly- identified fi ed recurrent gain at 6q27 involving MLLT4 (n = 10,-3%). Genomic complexity, del(16)(p13)/CREBBP and gain at 6q27 involving MLLT4, maintained their significance fi cance in multivariate analysis for survival outcome. Our study thus demonstrated that whole genome analysis of imbalances provides new insights to refine fi ne risk stratification fi cation in T-ALL. This trial was registered at www.ClinicalTrials.gov as #NCT00222027 and #NCT00327678, and as #FRALLE 2000T trial.